Research Analysts Set Expectations for DWTX FY2024 Earnings

Dogwood Therapeutics, Inc. (NASDAQ:DWTX) – Equities researchers at Zacks Small Cap issued their FY2024 EPS estimates for Dogwood Therapeutics in a research note issued to investors on Tuesday, March 18th. Zacks Small Cap analyst D. Bautz anticipates that the company will post earnings of ($6.43) per share for the year. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share. Zacks Small Cap also issued estimates for Dogwood Therapeutics’ Q4 2024 earnings at ($1.49) EPS, FY2025 earnings at ($4.57) EPS and FY2026 earnings at ($1.90) EPS.

Dogwood Therapeutics Stock Performance

Shares of NASDAQ DWTX opened at $6.33 on Friday. The company has a market capitalization of $8.43 million, a PE ratio of -0.97 and a beta of 2.07. The firm’s fifty day moving average is $7.28. Dogwood Therapeutics has a 52-week low of $1.62 and a 52-week high of $29.28.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Geode Capital Management LLC acquired a new position in shares of Dogwood Therapeutics, Inc. (NASDAQ:DWTX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,933 shares of the company’s stock, valued at approximately $27,000. Geode Capital Management LLC owned about 0.82% of Dogwood Therapeutics at the end of the most recent quarter. 9.05% of the stock is currently owned by institutional investors and hedge funds.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.